Related Experiment Video
Updated: Jul 24, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
Cascaded Multi-Modal Mixing Transformers for Alzheimer's Disease Classification with Incomplete Data
Linfeng Liu1, Siyu Liu2, Lu Zhang3
1Queensland Brain Institute, The University of Queensland, Australia.
Neuroimage
|July 8, 2023
Summary
This study introduces the Multi-Modal Mixing Transformer (3MT), a novel deep learning model for disease classification. 3MT effectively handles missing multi-modal data, improving accuracy for conditions like Alzheimer's Disease (AD).
Area of Science:
- Artificial Intelligence in Medicine
- Machine Learning for Healthcare
- Neuroscience and Medical Imaging
Background:
- Accurate medical classification relies on multi-modal data, but existing models struggle with missing data, leading to significant under-utilization.
- Deep learning performance is hampered by the scarcity of labeled medical images, especially when modalities are incomplete.
- A flexible multi-modal approach is needed to handle missing data in diverse clinical settings.
Purpose of the Study:
- To present the Multi-Modal Mixing Transformer (3MT), a novel deep learning model designed for disease classification using multi-modal data.
- To develop a method that effectively handles missing modalities, ensuring full data utilization.
- To evaluate 3MT's performance in classifying Alzheimer's Disease (AD) and predicting mild cognitive impairment (MCI) conversion.
Main Methods:
- Introduced the Multi-Modal Mixing Transformer (3MT), a transformer-based model for disease classification.
- Employed a novel Cascaded Modality Transformers architecture with cross-attention to integrate multi-modal information.
- Implemented a unique modality dropout mechanism to enhance robustness and independence against missing data.
Main Results:
- 3MT demonstrated state-of-the-art performance on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset for AD classification and MCI conversion prediction.
- The model achieved high performance on the Australian Imaging Biomarker & Lifestyle Flagship Study of Ageing (AIBL) dataset, even with missing data.
- The modality dropout mechanism ensured full data utilization in scenarios with missing modalities.
Conclusions:
- 3MT offers a versatile solution for multi-modal disease classification, adeptly handling missing data scenarios.
- The model's ability to mix arbitrary numbers of modalities and feature types enhances its applicability.
- 3MT represents a significant advancement in leveraging incomplete multi-modal data for improved medical classification and prediction.
Related Concept Videos
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Multi-input and Multi-variable systems
132
Cruise control systems in cars are designed as multi-input systems to maintain a driver's desired speed while compensating for external disturbances such as changes in terrain. The block diagram for a cruise control system typically includes two main inputs: the desired speed set by the driver and any external disturbances, such as the incline of the road. By adjusting the engine throttle, the system maintains the vehicle's speed as close to the desired value as possible.
In the absence...
In the absence...
132
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220

